Sign in
CompletedNo phase

Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents

Key facts

Who runs it
King's College London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
25 people enrolled
Started
1 Oct 2018
Ended
7 Sept 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lisdexamfetamine dimesylate
  • Guanfacine Extended Release Oral Tablet
  • Placebo
Record updated
12 August 2026

Who can take part

Age
8 years to 20 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age range: 8-20 years
  • Medication-naïve or non-medicated for two weeks or on stimulant medication, and willing to take the medication off for 48 hours before scans
  • Meeting DSM-5 diagnosis of ADHD
  • Score above clinical cut-off on the ADHD module of the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) (Kaufman et al., 1997)
  • Score above clinical cut-off for ADHD on the short forms of the Conners Parent Rating Scales, CPRS (Conners et al., 2008)
  • Score above cut-off on the ADHD Rating Scale, ADHD-RS (DuPaul, et al., 1998)
  • IQ > 70 as tested on the WASI-II (Wechsler et al., 1999)
  • Mood and depression symptoms will be allowed as long as they are not the primary diagnosis

Who cannot take part

  • Contraindication to MRI. i.e., previous implantation of metallic material, pacemaker, implanted medication pumps, neural stimulators, claustrophobia
  • Comorbidity with schizophrenia, bipolar disorder, learning disability, OCD, severe depression with current suicidal behaviour (as assessed by a clinical interview)
  • Neurological problems, i.e. a history of severe neurological illness, e.g. brain tumour, epilepsy or a history of symptomatic seizures, polyneuropathy etc
  • Other illness (cardiovascular, renal, hepatic, metabolic) that would impact the data integrity or safety of the subject (i.e. contraindicated to any of the treatments) as determined by the investigators
  • Contraindications for LISDEX and GXR use (i.e. advanced arteriosclerosis, agitated states, hyperexcitability, hyperthyroidism, moderate or severe hypertension, symptomatic cardiovascular disease)
  • IQ < 70 (Wechsler et al., 1999)
  • Substance abuse history
  • Unable to give informed assent or consent in the case of the parent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is not a clinical trial. The aim of this study is to understand the mechanism of action of two recently licensed drugs for ADHD on brain function. The investigators will compare the brain activation changes elicited by Guanfacine extended release (GXR; a non-stimulant drug) with the brain activation changes elicited by Lisdexamfetamine (LISDEX; a stimulant drug) and by placebo in 20 drug-free patients with ADHD using functional Magnetic Resonance Imaging (fMRI). For this purpose the investigators intend to scan participants during their performance of tasks of attention, working memory, and inhibition, which the investigators know from previous studies to elicit abnormal brain activation patterns in ADHD patients (Rubia et al., 2005; Smith et al., 2006).

The 3 groups in the trial

  • Lisdexamfetamine - PlaceboExisting treatment, for comparison

    Treatment: Lisdexamfetamine dimesylate and Placebo

  • Guanfacine - PlaceboExisting treatment, for comparison

    Treatment: Guanfacine Extended Release Oral Tablet and Placebo

  • Lisdexamfetamine - GuanfacineTreatment being tested

    Treatment: Lisdexamfetamine dimesylate and Guanfacine Extended Release Oral Tablet

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Experimental fMRI Study on the Comparison of the Brain Function Effects of a Single Dose of Guanfacine and Lisdexamfetamine Relative to Placebo in Children and Adolescents With ADHD.
Publications
Record updated
12 August 2026